Cost–Utility Analysis of the Newly Recommended Adjuvant Chemotherapy for Resectable Gastric Cancer Patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer

For patients in China with resectable disease, our results suggest that adjuvant chemotherapy with capecitabine plus oxaliplatin after a D2 gastrectomy is cost-saving and dominant in the long run on the basis of a current clinical trial, compared with treatment with a D2 gastrectomy alone. </AbstractSection> Copyright Springer International Publishing Switzerland 2014

MoreLess

Year of publication:	2014
Authors:	Chongqing, Tan ; Liubao, Peng ; Xiaohui, Zeng ; Jianhe, Li ; Xiaomin, Wan ; Gannong, Chen ; Siying, Wang ; Lihui, Ouyang ; Ziying, Zhao
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 32.2014, 3, p. 235-243
Publisher:	Springer

Online Resource

Check full text access |

More access options

Check Google Scholar

In libraries world-wide (WorldCat)

In German libraries (KVK)

subito order

I need help

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011001565